CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, ...

The TGA urged doctors to warn Ozempic users to 'be careful' and check the dose before administering it. Earlier this month, official data revealed more than 100 deaths in the United Kingdom had now ...

Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a ...